Atea eight-week hepatitis C regimen matches Epclusa in Phase 3 trial
Atea’s eight-week bemnifosbuvir and ruzasvir regimen matched 12-week Epclusa in a 905-patient Phase 3 hepatitis C trial.
Pharma & Biotech
Atea’s eight-week bemnifosbuvir and ruzasvir regimen matched 12-week Epclusa in a 905-patient Phase 3 hepatitis C trial.